Polynucleotide constructs and uses thereof

A polynucleotide and nucleotide technology, applied in the field of polynucleotide constructs, can solve the problems of transcription level and hypoxia-inducible ratio disappointment

Inactive Publication Date: 2001-10-24
OXFORD BIOMEDICA (UK) LTD
View PDF28 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, although studies to date have shown that it is possible to obtain hypoxia-triggered transcription in tumor cells, the obtained transcript levels and the hypoxia-induced ratio (hypoxic expression / normoxic expression) still disappointing
For example, WO-A-95 / 21927 tested constructs containing three copies of the mouse PGK HRE linked to the PGK-1 promoter, the 9-27 promoter, or the thymidine kinase gene promoter, but in hypoxic and the maximum induction ratio obtained under normoxic conditions was only about 18-fold

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polynucleotide constructs and uses thereof
  • Polynucleotide constructs and uses thereof
  • Polynucleotide constructs and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 21

[0051] Example 21 provides another example of HRE modification to enhance its hypoxic response.

[0052] A HRE may also comprise additional sequences, such as those with which it is naturally associated as part of an enhancer, or other sequences.

[0053] The expression level of the NOI or NOIs under the regulation of the specific polynucleotides of the present invention can be adjusted by manipulating the enhancer / promoter region. For example, different regions within a promoter region have different gene regulatory activities. The role of these different regions can often be assessed using vector constructs containing different variants of the promoter missing specific regions, (ie deletion analysis methods). This method can be used to determine, for example, the smallest region that confers tissue specificity or hypoxia inducibility.

[0054] Preferred promoters for use in the polynucleotides of the present invention are strong promoters such as viral promoters. For exam...

Embodiment 1

[0299] Example 1 - Construction of Optimal Hypoxia Response Element - Obhre11: A Mouse PGK HRE-Based Promoter

[0300] A variety of HRE constructs are known in the art. However, as mentioned above, to date, the degree of hypoxia-restricted expression directed by these sequences in constructs has not been entirely satisfactory. Appropriate HRE constructs should be able to direct high-level expression in a hypoxia-restricted manner. We therefore tested the hypoxia-specific activity of several different constructs, including two novel constructs based on three murine PGK HRE direct repeats cloned upstream of the SV40 promoter sequence, in the hope of obtaining a A sequence of desired properties.

[0301] Materials and Methods

[0302] Plasmid construction

[0303] Synthetic oligonucleotides containing the hypoxia response element (HRE) sequence were synthesized and cloned as a Bg1II / BamH1 fragment into the BamH1 site of the pGL3 promoter plasmid (Promega; Genbank accession no...

Embodiment 2

[0344] Example 2 - PGK HRE containing the transcription factor HIF-1 consensus sequence within OBhre11 can elicit hypoxia-mediated expression in macrophages, a cell that does not express HIF-1.

[0345] All of the HRE promoters described above contain the DNA motifs required for the binding of canonical HREs to the transcription factor HIF-1. This is a heterodimer composed of HIF 1α and HIF 1β, which belongs to the basic helix-loop-helix (bHLH) / PAS domain protein family (the original members of this gene family are: Period, ARNT and SIM). HIF 1α was originally identified as a protein capable of binding to the HRE of the erythropoietin gene in hepatoma cells (Wang et al., 1995), but it was later found to be involved in the regulation of other genes regulated by hypoxia in most cells. regulation of gene families.

[0346] Macrophages are able to infiltrate tumors to the extent that they constitute a substantial proportion of the total tumor mass. In particular macrophages can ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A polynucleotide is provided which comprises at least two repeats of a hypoxia response element (HRE), wherein the hypoxia-inducible factor consensus binding sites within each of the two repeats are separated by a spacer of at least 20 contiguous nucleotides. A polynucleotide is also provides which comprised at least three repeats of a phosphoglycerate kinase (PGK) hypoxia response element (HRE) operably linked to an SV40 promoter or an MLV promoter. The polynucleotide may be operably linked to a nucleic acid of interest to drive expression of the NOI in a cell under hypoxic conditions.

Description

field of invention [0001] The present invention relates to a polynucleotide construct, which contains a hypoxia response element operably linked to a promoter sequence, and is used for expressing therapeutic genes in target cells under hypoxic conditions such as tumor cells. Background of the invention [0002] Gene therapy refers to the method of treating or preventing diseases through gene transfer, and it is one of many methods used to treat various human malignancies. In detail, an increasing understanding of the molecular genetics of cancer has led to the emergence of a variety of new strategies for cancer treatment. Gene-based therapies currently being tested in clinical trials mainly involve ex vivo or ex vivo use of viral or liposomal vectors to deliver genes to tumors to: (i) replace tumor suppressor genes or inactivate oncogenes , (ii) expression of cytokines / vaccine known to activate or enhance anti-tumor immune mechanisms, (iii) increased drug sensitivity (e.g. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): C12N15/09A61K31/711A61K35/76A61K48/00A61P1/00A61P1/02A61P1/04A61P1/16A61P5/14A61P7/00A61P9/08A61P9/10A61P11/06A61P13/00A61P15/00A61P17/00A61P19/02A61P21/00A61P25/00A61P25/16A61P25/28A61P27/02A61P27/16A61P29/00A61P35/00A61P37/02A61P37/08A61P43/00C07K14/47C12N5/10C12N7/00C12N7/01C12N15/63C12N15/861C12N15/867C12R1/92
CPCC07K14/4702C12N2830/15A61K48/00C12N2830/42C12N2830/00C12N2830/48C12N2710/10343C12N2840/206C12N2830/008C12N2830/002C12N15/63C12N2830/50C12N15/86C12N2740/13043A61P1/00A61P1/02A61P1/04A61P1/16A61P11/06A61P13/00A61P15/00A61P17/00A61P19/02A61P21/00A61P25/00A61P25/16A61P25/28A61P27/02A61P27/16A61P29/00A61P35/00A61P37/02A61P37/08A61P43/00A61P5/14A61P7/00A61P9/08A61P9/10C12N15/113
InventorK·M·宾利S·内勒
OwnerOXFORD BIOMEDICA (UK) LTD